Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Work In Process (2023 - 2026)

Catalyst Pharmaceuticals filings provide 4 years of Work In Process readings, the most recent being $2.8 million for Q1 2026.

  • On a quarterly basis, Work In Process fell 34.42% to $2.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.8 million, a 34.42% decrease, with the full-year FY2025 number at $3.9 million, up 12.37% from a year prior.
  • Work In Process hit $2.8 million in Q1 2026 for Catalyst Pharmaceuticals, down from $3.9 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $5.3 million in Q2 2025 to a low of $2.8 million in Q1 2026.
  • Median Work In Process over the past 4 years was $4.0 million (2024), compared with a mean of $4.1 million.
  • Biggest five-year swings in Work In Process: skyrocketed 32.89% in 2025 and later crashed 34.42% in 2026.
  • Catalyst Pharmaceuticals' Work In Process stood at $4.6 million in 2023, then fell by 24.67% to $3.4 million in 2024, then increased by 12.37% to $3.9 million in 2025, then dropped by 28.44% to $2.8 million in 2026.
  • The last three reported values for Work In Process were $2.8 million (Q1 2026), $3.9 million (Q4 2025), and $4.6 million (Q3 2025) per Business Quant data.